Ferring Signs Global Agreement to Commercialise Novel Gene Therapy for Bladder Cancer Patients
Ferring Pharmaceuticals today announced the signing of an agreement giving the company the option to secure global commercialisation rights to nadofaragene firadenovec/Syn3 (rAd-IFN/Syn3), a novel gene therapy being developed by FKD Therapies Oy (FKD) as a treatment for patients with high-grade non-muscle invasive bladder cancer (NMIBC), who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. This option is exercisable on marketing approval from the US FDA. Ferring will create a new US oncology division with the specialist knowledge and presence to introduce novel advanced therapies to the market.
rAd-IFN/Syn3 is currently undergoing Phase 3 development in the US under the sponsorship of Finnish gene therapy specialists FKD. The results of the earlier Phase 2 trial, published in the Journal of Clinical Oncology, reported 35% of BCG unresponsive NMIBC bladder cancer patients given one dose of rAd-IFN/Syn3 every three months, were free of high-grade disease at one year1. The ongoing Phase 3 study is designed to establish the efficacy and safety of the product. rAd-IFN/Syn3 has been awarded Fast Track and Breakthrough Therapy designations by the FDA.
“We are excited about the potential to commercialise rAd-IFN/Syn3, a novel gene therapy for bladder cancer patients,” said Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals. “The gene therapy sector is growing rapidly and building a presence in this specialised area is a very positive opportunity for Ferring.”
Bladder cancer is one of the most frequently occurring cancers with an estimated 430,000 new cases being reported worldwide each year2. It is the fourth most common cancer in men in the US3 and is the most expensive cancer to treat on a life-time basis, with a high burden on patients, their relatives and healthcare systems4. In high-grade NMIBC patients, BCG is the gold standard treatment and although effective, over 60% of cases eventually re-occur5, 6. The outcome for such patients is poor, with total cystectomy (complete removal of the bladder) to prevent the cancer spreading to other organs generally being the next treatment option. As such, the BCG unresponsive population is one of high unmet clinical need.
“Today, bladder cancer patients have very limited medical options and new treatments that delay or prevent total removal of the bladder and improve clinical outcomes are urgently needed for patients,” said Professor Klaus Dugi, Chief Medical Officer, Ferring Pharmaceuticals. “Phase 2 clinical results for rAd-IFN/Syn3 were very encouraging and we look forward to the Phase 3 data.”
Gene therapy is one of a new class of therapeutic treatments known as advanced therapy medicinal products. rAd-IFN/Syn3 is built on adenoviral vector technology, a non-integrating vector, and results in enhanced expression of the therapeutic protein interferon alfa 2b. To date, it has completed three clinical trials in the US.
rAd-IFN/Syn3 (nadofaragene firadenovec/Syn3) is an investigational gene therapy consisting of an adenovirus containing the gene interferon alfa-2b. It is administered by catheter into the bladder, where the virus enters the cells of the bladder wall. Inside the cells, the virus breaks down leaving the active gene to do its work. The internal gene/DNA machinery of the cells picks up the gene and translates its DNA sequence, resulting in the cells secreting high quantities of interferon alfa-2b protein, a naturally occurring protein the body uses to fight cancer. This novel gene therapy approach turns the patient's own bladder wall cells into multiple interferon microfactories, enhancing the body's natural defences against the cancer. The Phase 3 trial for rAd-IFN/Syn3 opened in 2016 with up to 150 patients to be enrolled across 35 centers in the US.
About FKD Therapies Oy
FKD Therapies Oy is a gene therapy company, located in Kuopio, Finland and is the sponsor and developer of rAd-IFN/Syn3.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
# # #
1 Shore ND, Boorjian AS, Canter KD, Ogan K, Karsh IL, Downs MT, et al. Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. J Clin Oncol [Internet]. 2017 October [cited 2018 Mar 19]; 35(30):3410-3416. Available from http://ascopubs.org/doi/full/10.1200/JCO.2017.72.3064
2 Antoni S, Ferlay J, Soerjomataram I, Znaor A, Ahmedin J, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol [Internet]. 2017 Jan [cited 2018 Mar 19]; 71(1):96-108. Available from: http://www.europeanurology.com/article/S0302-2838(16)30280-9/fulltext
3 Colorectal cancer can be prevented. Get screened [Internet]. United States: American Cancer Society; 2018. Key Statistics for Bladder Cancer; 2018 Jan 4 [cited 2018 March 19]. Available from: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html
4 Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol [Internet]. 2009 Mar [cited 2018 Mar 19]; 27(3): 295-300. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694315/
5 Maruf M, Brancato S, Agarwal P. Non invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med [Internet]. 2016 Jun [cited 2018 March 19]; 13(2): 194–205. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944546/
6 Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M 1, Fritschi U, et al. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients. Clin Cancer Res [Internet]. 2017 Feb [cited 2018 Mar 19]; 23(3): 717-725. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27521445
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Sharjah Announces its First Fully Integrated Investors Services Centre19.9.2018 16:36 | Tiedote
In a bid to support prospective foreign investors expand their international growth ambition in the UAE, its third largest emirate, Sharjah, has announced the launch of a digitally robust business facilitation initiative, the Investors Services Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005444/en/ General photo of Sharjah (Photo: Shurooq) The emirate’s investment and development authority, Shurooq, has partnered with Injazat Services, to develop this high-end facility to offer an exhaustive list of fully integrated business consultancy services, which will specially benefit new players on the UAE turf. The office will serve as a key access point for global business owners and investors in Sharjah, and serviced by a highly trained staff, will play an integral role in facilitating high-level and mid-level investments across a variety of sectors within the emirate. Through this service centre, investors will b
ISACA Research: Only 4 in 10 Tech Professionals Confident in Security of Their Organizations’ AI Deployments19.9.2018 16:00 | Tiedote
Despite heightened interest in enterprise deployment of artificial intelligence, only 40 percent of respondents to ISACA’s second annual Digital Transformation Barometer express confidence that their organizations can accurately assess the security of systems based on AI and machine learning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180919005423/en/ ISACA's 2018 Digital Transformation Barometer looks at companies' digital transformation journeys, including the technologies with the biggest impacts and the positive effect of digitally literate leaders. (Graphic: Business Wire) This becomes especially striking given the potential for serious consequences from maliciously trained AI; survey respondents identify social engineering, manipulated media content and data poisoning as the types of malicious AI attacks that pose the greatest threat within the next five years. AI/machine learning also continued to rise toward the
Dutch Shareholder Foundation Achieves Significant Victory For Petrobras Investors With Billions In Losses In European Securities Fraud Litigation19.9.2018 15:17 | Tiedote
International Securities Associations & Foundations Management Company (ISAF) Today the District Court in Rotterdam has ruled in favor of Stichting Petrobras Compensation Foundation (SPCF or Foundation) regarding arguments to establish jurisdiction in the Netherlands for eligible Petrobras investors seeking compensation for losses related to the “Lavo Jato” or “Operation Car Wash” scandal. Also the Court ruled that the arbitration clause in Petrobras’ Articles cannot preclude the SPCF from bringing a claim against Petrobras on behalf of aggrieved Petrobras shareholders. ISAF congratulates SPCF on this important legal decision and reminds investors that losses from investments in primary shares of Petrobras traded in Brazil on the Brasil Bolsa Balcão S.A. or B3 - Brazil (formerly BM&FBOVESPA) and via linked markets in Europe and also Bonds bought outside the US, will not be compensated under the US $3 billion settlement in the US. Robert Frome, Chairman of ISAF, commented: “The ruling a
Cerebrum Therapeutics Wins Biotech Startup Pitch Competition Co-Sponsored by Scientist.com and iPEPS-ICM19.9.2018 15:06 | Tiedote
Scientist.com, the life science industry’s leading online marketplace for outsourced research, and the Brain and Spine Institute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in France, announced that Cerebrum Therapeutics won a biotech pitch competition with a prize package that includes 6 months free rent at iPEPS’ state-of-the-art facilities located in Paris’ 13th district and $10K USD in research services provided through the Scientist.com marketplace. Runner-up Cairn Biosciences will receive 3 months free rent at iPEPS and $6K USD in research services through Scientist.com. “It is an honor to be recognized by the Brain and Spine Institute and Scientist.com for our efforts to develop novel treatments for brain diseases and injuries,” said Vincent Serra, PhD, CEO and Co-Founder of Cerebrum Therapeutics. “The prizes will go a long way toward accelerating our breakthrough approach to testing promising chemical and biological properties in the CNS f
IBC Grows in Scope, Reach and Diversity19.9.2018 13:03 | Tiedote
IBC2018 has closed its doors for this year and has delivered another great event with visitor figures of 55,884. As well as providing a host of new initiatives this year, the exhibition grew by 667m2 and conference delegates were up by 14% year on year. One of the most important growth figures lies in the diversity of its content with a targeted effort increasing women speakers at the conference up from 14% to 37%. The IBC International Honour for Excellence saw its first-ever woman recipient this year, too. Joan Ganz Cooney was the co-creator of the global phenomenon that is Sesame Street, 50 years ago and her trophy was collected on her behalf by one of the street’s longest residents, Ernie. The IBC App has provided real networking opportunities, with more than 91,000 interactions on the matchmaking platform. In addition, IBC trended number one on Twitter in the Netherlands on several days of the convention, with 185 million potential impressions and over 250,000 video views. Engagem
NanoSteel Launches ‘Formetrix, Inc.,’ to Commercialize Additive Manufacturing Metals19.9.2018 12:15 | Tiedote
NanoSteel®, the leader in nanostructured steel materials, today announced the spinout of its Additive Manufacturing (AM) business unit into a new corporation named, ‘Formetrix™.’ Led by an industrial leader in Additive Manufacturing and including other investors Cycad Group and SPDG, Formetrix closed its Series A capital raise to accelerate the commercialization of Formetrix’s steel alloys for 3D printing processes. Over the last four years, the team developed novel alloys with exceptional material properties that current 3D printable or metal injection molded alloys do not offer. Leveraging NanoSteel’s decade long expertise in patented steel alloy design, Formetrix’s metal powder portfolio provides an attractive combination of benefits such as higher hardness, higher ductility and higher wear resistance compared to existing alternatives. The company’s initial industry focus is on materials for hot and cold forming tool and dies (i.e. molding, casting and stamping) within the automotiv
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme